@DrNancySweitzer
banner
drnancysweitzer.bsky.social
@DrNancySweitzer
@drnancysweitzer.bsky.social
Heart Failure Transplant Cardiologist, Clinical Trialist, Editor-in-Chief Circulation: Heart Failure, Knitter, Contemporary Fiction reader
Much needed, and reassuring, real-world data on the patient experience with mavacamten @CircHF
January 23, 2025 at 12:22 AM
Reposted by @DrNancySweitzer
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program
www.ahajournals.org/doi/10.1161/...
Mavacamten: Real-World Experience From 22 Months of the Risk Evaluation and Mitigation Strategy (REMS) Program | Circulation: Heart Failure
BACKGROUND: Mavacamten is the only cardiac myosin inhibitor approved by the U.S. Food and Drug Administration for the treatment of patients with symptomatic New York Heart Association class II–III obs...
www.ahajournals.org
January 22, 2025 at 2:11 PM
My privilege to meet with this brilliant cardiologists, scientists, ICU docs and nephrologists @Aha2024 #WomenAsOne #cardiosky
November 18, 2024 at 3:05 AM
Sometimes in the whirlwind of travel woes you forget how wonderful it is to be together in person! #AHA2024 #cardiosky
November 18, 2024 at 2:45 AM